Carnegie Investment Counsel Makes New $314,000 Investment in Sanofi (NASDAQ:SNY)

Key Points

• Carnegie Investment Counsel has acquired a new position in Sanofi, purchasing 5,656 shares valued at approximately $314,000 in the first quarter.
• Sanofi's recent quarterly earnings reported earnings per share (EPS) of $0.94, exceeding estimates by $0.04, despite a 11% decline in revenue year-over-year.
• Analysts maintain a generally positive outlook on Sanofi, with a consensus rating of "Buy" and an average target price of $62.00.

Carnegie Investment Counsel bought a new position in Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,656 shares of the company's stock, valued at approximately $314,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of SNY. Bessemer Group Inc. raised its position in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after buying an additional 242 shares in the last quarter. Golden State Wealth Management LLC raised its stake in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after buying an additional 264 shares in the last quarter. Wayfinding Financial LLC bought a new stake in shares of Sanofi in the 1st quarter worth $63,000. Finally, Tsfg LLC raised its stake in shares of Sanofi by 1,107.0% in the 1st quarter. Tsfg LLC now owns 1,207 shares of the company's stock worth $67,000 after buying an additional 1,107 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SNY shares. Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research report on Monday, June 2nd. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $62.00.

Sanofi Price Performance

NASDAQ SNY opened at $50.37 on Friday. The stock's 50-day moving average price is $49.54 and its two-hundred day moving average price is $52.13. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The company has a market cap of $123.53 billion, a PE ratio of 17.99, a PEG ratio of 1.15 and a beta of 0.48. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.78 EPS. On average, analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.